SSRIs联合α1受体阻滞剂治疗继发性早泄合并下尿路症状患者疗效观察OA

Objective To investigate the clinical efficacy and safety of selective serotonin reuptake inhibitors(SSRIs)combined with α1-receptor blockers for the treatment of patients with secondary premature ejaculation(SPE)and concomitant lower urinary tract symptoms(LUTS).Methods A total of 57 patients with SPE and concomitant LUTS were randomly divided into three groups:SSRIs group(n=20),α1-receptor blockers group(n=17),or drug combination group(n=20).Patients in the SSRIs group received Sertraline Hydrochloride Tablets,those in the α1-receptor blockers group received Tamsulosin Hydrochloride Sustained-Release Tablets,and those in the drug combination group received both 2 drugs as above.All patients among the three groups as above were treated continuously for 12 weeks.Indices including intravaginal ejaculatory latency time(IELT),International Prostate Symptom Scale(IPSS)score,premature ejaculation diagnostic tool(PEDT)score,and seminal vesicle width were compared between the three groups before and after treatment.In addition,the clinical global impression of change(CGIC)effective rate and the occurrence of adverse reactions were also compared between the three groups.Results Compared with before treatment,IELT was prolonged and PEDT score was reduced in all three groups after treatment,moreover,IPSS score was reduced in the drug combination group and the α1-receptor blockers group(P<0.05),whereas no statistically significant difference was observed in seminal vesicle width before and after treatment in any of the three groups(P>0.05).After treatment,IELT in the drug combination group was longer than that in the α1-receptor blockers group and the SSRIs group,and PEDT score in the drug combination group was lower than that in the remaining two groups(P<0.05).After treatment,IPSS score in the SSRIs group was higher than that in the α1-receptor blockers group and the drug combination group(P<0.05).No statistically significant difference was found between the three groups in seminal vesicle width and CGIC effective rate after treatment,or total incidence rate of adverse reactions during treatment(P>0.05).Conclusion Both SSRIs and α1-receptor blockers can improve symptoms in SPE patients and concomitant LUTS,and the drug combination therapy demonstrates superior efficacy to monotherapy,with a favorable safety profile.The therapeutic effect is independent of changes in seminal vesicle width.